



OrganTrans


Process for organoids transplantation

New regenerative therapy

Autonomous self-assembly

Stem cells-derived organoids

Standardized organoids & automation



Biomimicry

FDA-approved materials

Vascularization



ORGANTRANS offers a disruptive alternative to donor organs for patients with chronic or end-stage liver diseases who still have residual healthy tissue by isolating autologous liver stem cells.

The project develops a liver tissue printing platform under the "compassionate use exemption" umbrella, finding its end use within three European transplant centers. Uniquely the platform combines autonomous self-assembly with biomimicry for tissue engineering.

The initiative covers the entire value chain, from cell source, standardized production and sorting of organoids, biomaterials, vascularization architecture, bioprinting and tissue maturation to in vitro/in vivo testing of the liver tissue transplant.

CONTACTS

Dr. Gilles Weder

Project Coordinator
CSEM

gilles.weder@csem.ch
+41 79 176 54 70

Dr. Mariana Pacheco Blanco

Project Manager
AMIRES s.r.o.
pacheco@amires.eu



OrganTrans

Process for organoids transplantation

WWW.ORGANTRANS.EU

THE TEAM



Utrecht University

csem

KUGELMEIERS



DWI

Leibniz-Institute for
Interactive Materials

AMIRÈS

REGEN+U

